Literature DB >> 9788250

Stable transfection of fatty acid translocase (CD36) in a rat heart muscle cell line (H9c2).

F A Van Nieuwenhoven1, J J Luiken, Y F De Jong, P A Grimaldi, G J Van der Vusse, J F Glatz.   

Abstract

Fatty acid translocase (FAT/CD36) is a membrane protein putatively involved in the transmembrane transport of long-chain fatty acids. We tested the hypothesis that expression of this protein in H9c2, a rat heart cell line normally not expressing FAT, would increase cellular palmitate uptake. We were able to stably transfect H9c2 cells with FAT, yielding 15 cell lines showing varying levels of FAT expression. The uptake and metabolism of palmitate was first studied in the non-transfected H9c2 cells and in two FAT-transfected cell lines. In each case, uptake of palmitate was found to be linear in time for at least 30 min and the uptake rate was saturable with increasing palmitate concentrations. Using conditions under which the maximal capacity of intracellular palmitate handling was not fully utilized, we tested 7 out of 15 FAT-transfected cell lines with varying FAT expression levels. No significant correlation was found between the level of FAT expression and the rate of palmitate uptake. In conclusion, we found that palmitate uptake by H9c2 cells occurs mainly by passive diffusion. Fatty acid translocase (FAT) transfection did not significantly increase the palmitate uptake rate, raising the possibility that H9c2 cells lack a protein (or set of proteins) that acts as an obligatory partner of FAT in long-chain fatty acid transport from the extracellular compartment to the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788250

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

Review 1.  Role of plasma membrane transporters in muscle metabolism.

Authors:  A Zorzano; C Fandos; M Palacín
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

Review 2.  Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization.

Authors:  Jan F C Glatz; Joost J F P Luiken
Journal:  J Lipid Res       Date:  2018-04-07       Impact factor: 5.922

3.  A sensitive immunoassay for rat fatty acid translocase (CD36) using phage antibodies selected on cell transfectants: abundant presence of fatty acid translocase/CD36 in cardiac and red skeletal muscle and up-regulation in diabetes.

Authors:  M M Pelsers; J T Lutgerink; F A Nieuwenhoven; N N Tandon; G J van der Vusse; J W Arends; H R Hoogenboom; J F Glatz
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  The role of hyperglycemia in FAT/CD36 expression and function.

Authors:  Min Chen; Ying-Kui Yang; Tara J Loux; Keith E Georgeson; Carroll M Harmon
Journal:  Pediatr Surg Int       Date:  2006-07-13       Impact factor: 1.827

5.  Purification, immunochemical quantification and localization in rat heart of putative fatty acid translocase (FAT/CD36).

Authors:  Joep F F Brinkmann; Maurice M A L Pelsers; Frans A van Nieuwenhoven; Narendra N Tandon; Ger J van der Vusse; Jan F C Glatz
Journal:  Mol Cell Biochem       Date:  2006-03-16       Impact factor: 3.396

Review 6.  New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36.

Authors:  Joep F F Brinkmann; Nada A Abumrad; Azeddine Ibrahimi; Ger J van der Vusse; Jan F C Glatz
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 7.  Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins.

Authors:  J J Luiken; F G Schaap; F A van Nieuwenhoven; G J van der Vusse; A Bonen; J F Glatz
Journal:  Lipids       Date:  1999       Impact factor: 1.646

8.  Regulation of FAT/CD36 mRNA gene expression by long chain fatty acids in the differentiated 3T3-L1 cells.

Authors:  Yingkui Yang; Min Chen; Tara J Loux; Carroll M Harmon
Journal:  Pediatr Surg Int       Date:  2007-05-22       Impact factor: 2.003

9.  Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.

Authors:  Elisa Ramírez; Mercedes Klett-Mingo; Sara Ares-Carrasco; Belén Picatoste; Alessia Ferrarini; Francisco J Rupérez; Alicia Caro-Vadillo; Coral Barbas; Jesús Egido; José Tuñón; Óscar Lorenzo
Journal:  Cardiovasc Diabetol       Date:  2013-11-21       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.